A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome

Clinical trial NCT07219602 · RECRUITING

Trial details

NCT number: NCT07219602
Sponsor: NewAmsterdam Pharma
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Lipidemia Type 2 Diabetes (T2DM)Metabolic Syndrome (MetS)

Start date: 2025-12-11
Primary completion: 2028-03-01
Enrollment: 300

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.